Edison Scientific

Edison Scientific is launching Kosmos, an autonomous AI agent built for pharmaceutical R&D teams that runs the kind of literature review, data analysis, and hypothesis generation that normally consumes weeks of researcher time. Incyte and Edison Scientific have entered a strategic collaboration to integrate the Kosmos AI platform across Incyte's research and development operations , with work initially focused on target discovery, validation, and predictive models of therapeutic performance trained on translational and clinical data . The launch matters because it is the first time Kosmos is being deployed across an active pharma pipeline, giving Edison a live test of whether agentic systems can meaningfully shorten timelines in commercial drug development. The technical premise is a persistent world model that updates as the agent runs experiments and analyses, so each result reshapes the next set of questions Kosmos asks. Edison frames Kosmos as the most compute-intensive language agent released so far, designed to produce complex outputs that require multiple chained steps of reasoning . The company has previously claimed that a single Kosmos run can read 1,500 papers and write 42,000 lines of code, with users estimating it does roughly six months of work in a day , framing that Edison is now putting to the test inside Incyte's programs. Edison is led by CEO Sam Rodriques and co-founder Andrew White, and is the commercial spinout of FutureHouse, the AI scientist nonprofit backed by former Google CEO Eric Schmidt and co-founded by Rodriques, a former group leader at The Francis Crick Institute . For founders and operators watching the AI-for-science space, the Incyte deal is a useful signal of how a large pharma is willing to wire an outside agent into its discovery stack rather than build the equivalent internally.